| Name | Title | Contact Details |
|---|---|---|
Jeff Sidell |
Chief Technology Officer | Profile |
Eric Whitford |
IT Director | Profile |
Nitin Uplekar |
Chief Information Officer | Profile |
Jonathan Shough |
President of Technology Solutions | Profile |
Quotient Bioresearch is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Headway.co is a digital marketing agency that offers holistic services to help businesses scale their growth. From innovative digital strategies to custom web design and development, Headway.co specializes in conversion optimization and delivering meas...
Immune-Tree Inc is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.